This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Bernstein Remains a Hold on Amgen (AMGN)

Tipranks - Tipranks - Thu Jun 11, 6:20AM CDT

Bernstein analyst Courtney Breen maintained a Hold rating on Amgen yesterday. The company’s shares closed yesterday at $344.57.

Introducing TipRanks MCP for Agents

According to TipRanks, Breen is a 5-star analyst with an average return of 20.4% and an 86.27% success rate. Breen covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Merck & Company, and Pfizer.

Amgen has an analyst consensus of Moderate Buy, with a price target consensus of $359.96.

See the top stocks recommended by analysts >>

Based on Amgen’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $8.62 billion and a net profit of $1.82 billion. In comparison, last year the company earned a revenue of $8.15 billion and had a net profit of $1.73 billion

Read More on AMGN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).